APG Asset Management N.V. boosted its position in shares of Incyte Co. (NASDAQ:INCY) by 3.3% in the fourth quarter, Holdings Channel reports. The firm owned 46,408 shares of the biopharmaceutical company’s stock after purchasing an additional 1,500 shares during the period. APG Asset Management N.V.’s holdings in Incyte were worth $2,582,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Two Sigma Investments LP grew its stake in Incyte by 88.2% in the fourth quarter. Two Sigma Investments LP now owns 1,211,513 shares of the biopharmaceutical company’s stock valued at $77,040,000 after purchasing an additional 567,826 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Incyte by 351.2% in the 3rd quarter. AQR Capital Management LLC now owns 594,791 shares of the biopharmaceutical company’s stock valued at $41,088,000 after buying an additional 462,965 shares in the last quarter. Worldquant Millennium Quantitative Strategies LLC grew its stake in shares of Incyte by 756.9% in the 3rd quarter. Worldquant Millennium Quantitative Strategies LLC now owns 344,645 shares of the biopharmaceutical company’s stock valued at $23,808,000 after buying an additional 304,424 shares in the last quarter. Polar Capital LLP grew its stake in shares of Incyte by 63.9% in the 4th quarter. Polar Capital LLP now owns 757,652 shares of the biopharmaceutical company’s stock valued at $48,179,000 after buying an additional 295,310 shares in the last quarter. Finally, Prudential PLC bought a new stake in shares of Incyte in the 4th quarter valued at approximately $17,584,000. 91.58% of the stock is owned by hedge funds and other institutional investors.
Several brokerages recently weighed in on INCY. BidaskClub lowered shares of Incyte from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Gabelli raised shares of Incyte from a “hold” rating to a “buy” rating and set a $105.00 target price for the company in a research report on Wednesday, January 23rd. Guggenheim upgraded shares of Incyte from a “neutral” rating to a “buy” rating in a research note on Thursday, January 3rd. JPMorgan Chase & Co. restated a “buy” rating on shares of Incyte in a report on Thursday, January 10th. Finally, ValuEngine raised shares of Incyte from a “sell” rating to a “hold” rating in a research note on Tuesday, December 11th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $89.89.
Shares of Incyte stock opened at $84.76 on Friday. The company has a quick ratio of 4.29, a current ratio of 4.31 and a debt-to-equity ratio of 0.01. Incyte Co. has a 1-year low of $57.00 and a 1-year high of $88.83. The firm has a market capitalization of $17.83 billion, a PE ratio of 103.37 and a beta of 1.39.
Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Thursday, February 14th. The biopharmaceutical company reported $0.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.25 by $0.15. The business had revenue of $528.40 million during the quarter, compared to the consensus estimate of $485.72 million. Incyte had a net margin of 5.82% and a return on equity of 6.17%. Incyte’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.02 EPS. As a group, analysts anticipate that Incyte Co. will post 1.27 EPS for the current year.
In other Incyte news, insider Paul Trower sold 5,813 shares of Incyte stock in a transaction that occurred on Tuesday, January 15th. The stock was sold at an average price of $75.00, for a total value of $435,975.00. Following the transaction, the insider now directly owns 19,713 shares of the company’s stock, valued at approximately $1,478,475. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Paula J. Swain sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $87.01, for a total value of $870,100.00. Following the transaction, the executive vice president now owns 38,295 shares of the company’s stock, valued at $3,332,047.95. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,354 shares of company stock valued at $5,695,424. Company insiders own 17.10% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “APG Asset Management N.V. Grows Position in Incyte Co. (INCY)” was originally published by Stock Observer and is owned by of Stock Observer. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.thestockobserver.com/2019/04/07/apg-asset-management-n-v-grows-position-in-incyte-co-incy.html.
Incyte Company Profile
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Further Reading: Why do companies issue stock splits?
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.